MedTrace Logo

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

NCT04447092 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2024-04-19

No results posted yet for this study

Summary

This is an open-label, phase 2 study of Pembrolizumab in combination with chemotherapy in chemotherapy-naïve advanced pancreatic cancer

Conditions

Interventions

DRUG

Gemcitabine

Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)

DRUG

Nab-paclitaxel

Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)

DRUG

Pembrolizumab

Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)

DRUG

Oxaliplatin

Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)

DRUG

Leucovorin

Leucovorin 400 mg/m2 iv D1 (every 2 weeks)

DRUG

Irinotecan

Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)

DRUG

5FU

5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Do-Youn Oh, M.D., PhD. · Seoul National University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2024-12-31
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04447092 on ClinicalTrials.gov